Eli Lilly (LLY) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $6.6 billion.
- Eli Lilly's Income from Continuing Operations rose 5052.16% to $6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $20.6 billion, marking a year-over-year increase of 9490.08%. This contributed to the annual value of $20.6 billion for FY2025, which is 9490.08% up from last year.
- According to the latest figures from Q4 2025, Eli Lilly's Income from Continuing Operations is $6.6 billion, which was up 5052.16% from $5.6 billion recorded in Q3 2025.
- In the past 5 years, Eli Lilly's Income from Continuing Operations registered a high of $6.6 billion during Q4 2025, and its lowest value of -$57.4 million during Q3 2023.
- In the last 5 years, Eli Lilly's Income from Continuing Operations had a median value of $1.8 billion in 2022 and averaged $2.4 billion.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 10395.4% in 2023, then surged by 179041.81% in 2024.
- Over the past 5 years, Eli Lilly's Income from Continuing Operations (Quarter) stood at $1.7 billion in 2021, then rose by 12.26% to $1.9 billion in 2022, then rose by 12.98% to $2.2 billion in 2023, then soared by 101.43% to $4.4 billion in 2024, then skyrocketed by 50.52% to $6.6 billion in 2025.
- Its Income from Continuing Operations stands at $6.6 billion for Q4 2025, versus $5.6 billion for Q3 2025 and $5.7 billion for Q2 2025.